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Abstract
Fibroadenomas are common benign breast tumours that display a characteristic pathological
morphology, although several epithelial and stromal variations exist. A very rare histological finding
is the presence of multinucleated giant cells throughout the stroma of a benign fibroadenoma. Cells
of this type, which are more commonly found incidentally within the interlobular stroma of breast
tissue, are benign and should not be mistaken for malignant cells on microscopic examination.
Unfortunately a lack of awareness of this pathological entity can lead to diagnostic confusion
amongst pathologists resulting in the multinucleate giant cells being mistaken for highly mitotic cells
and consequently the fibroadenoma being mistaken for a malignant lesion. This may have serious
implications for the subsequent management of the patient. The presence of this unusual cell type
in the stroma does not alter the prognosis of otherwise benign lesion. We encountered two such
cases at our institution in a six month period recently. We present their histories along with
relevant radiological, microscopic and immunohistochemical features, followed by a discussion of
this unusual pathological entity.
Case Presentation
A 42 year old female was referred to the Breast Clinic for
assessment of a palpable right breast lump. She had
detected the breast lump six weeks previously during rou-
tine self examination and did not complain of any mast-
algia, nipple discharge, skin changes or systemic
symptoms. She had no personal or family history of breast
cancer and had never used the oral contraceptive pill
(OCP) or hormone replacement therapy. Clinical exami-
nation revealed a non-tender, mobile 2 cm solid mass in
the upper outer quadrant of the right breast. Mammogra-
phy and Ultrasonography confirmed the presence of a 2
cm solid mass in the right upper quadrant (Figures 1a,
1b). Core biopsy demonstrated fibroadipose tissue with
stromal calcification. Given the clinical and pathological
findings the patient opted for surgical excision of the
lesion. Gross examination of the specimen revealed a well
circumscribed firm nodule measuring 2.5 × 2.0 cm. The
cut surface was firm and tan-gray in colour, with a
whorled appearance. Microscopically the tumour shows a
benign epithelial component with elongated, branching
ducts and cellular stroma. The stroma was composed of
cells with giant nuclei some of which are multi-nucleated.
Mitosis of these cells was not seen (Figures 2a, 2b, 2c). The
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stromal cells stained negative for the Estrogen and Proges-
terone receptors (ER, PR respectively) Pancytokeratin
(AE1/3 & CAM 5.2), Muscle Specific Actin, S100 and
desmin, and stained positive for Vimentin; a general mes-
enchymal marker and suggestive of cells of myofibroblas-
tic origin (Figures 3a, 3b, 3c). The conclusive diagnosis
was that of a fully excised benign fibroadenoma, with
multinucleated giant cells throughout its stroma. She
made an uneventful postoperative recovery and follow-up
has shown no recurrence of the lesion.
The second case is that of a 48 year old lady referred to the
Breast Clinic with a two month history of a left breast
lump and mastalgia. She denied nipple discharge, nipple
inversion or skin changes. She had no relevant past medi-
cal history, had never used the OCP and had no family
history of breast cancer. On examination, a 1.5 cm tender
solid mass was palpable in the upper inner quadrant of
the left breast. Ultrasonography revealed the presence of a
number of small benign cysts with a single solid lobulated
mass lesion at 12 o'clock measuring 17 mm in diameter
Radiology images from 2 cases presenting with a breast mass Figure 1
Radiology images from 2 cases presenting with a breast mass. a. Case 1. Mammogram of right breast. b. Case 1. Ultra-
sound of right breast. c. Case 2. Mammogram of left breast. d. Case 2. Ultrasound of left breast.
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(Figure 1c). Mammography confirmed the presence of a
smooth mass measuring 2 cm in diameter in the retro-are-
olar region of left breast (Figure 1d).
Ultrasound guided tru-cut biopsy was performed. Histo-
logical analysis demonstrated cores and fragments of
fibroadenomatous breast tissue, with numerous uni-
formly giant and multi-nucleated cells intermingled with
fibroblasts throughout the stroma, (Figures 2d, 2e, 2f).
Immunohistochemistry staining of these giant cells was
negative again for ER & PR status, pancytokeratin (AE1/3
& CAM 5.2) and muscle specific actin (Fig 3d, 3e) as well
as for S100 protein and desmin. They showed only posi-
tivity with vimentin (Figures 3f). No malignant changes
were seen and a diagnosis of benign fibroadenoma of the
left breast with a multi-nucleated giant cell stroma was
made. The patient declined surgical excision of the lesion.
Discussion
In 1979 Rosen first described the presence of Multinucle-
ated Stromal Giant Cells (MSGCs) in the breast, as an inci-
dental finding in breast specimens from 14 patients with
breast carcinoma [1]. The tissue foci containing these
atypical MSGCs were located in otherwise normal areas of
the mammary gland and were usually distinct from the
carcinomata. Rosen concluded that these cells represented
a non-neoplastic and possibly reparative process. Subse-
quently MSGCs have been described in several other
breast lesions raising an interesting differential diagnosis,
mainly with benign disorders but also on occasion in
association with malignant lesions [2-5]. MSGCs similar
to those occurring in breast tissue have also been found to
occur in the vagina, uterine cervix, nasal polyps, urinary
bladder epithelium, anus, and in lesions of the oral cavity.
Their presence in other benign tumours has also been
described, including pleomorphic lipomas, leiomyomas
Microscopy of breast core biopsies Figure 2
Microscopy of breast core biopsies. a. Case 1 (H&E stain, × 200). b. Case 1 (H&E stain, × 200). c. Case 1 (H&E stain, × 
400). d. Case 2 (H&E stain, × 200). e. Case 2 (H&E stain, × 200). f. Case 2 (H&E stain, × 400).
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and fibromas, schwannomas, and in variants of der-
matofibromas with atypical cells. The pathogenesis of
MSGCs in breast tissue and in the lower female genital
tract is unclear. Rosen postulated that the MSGCs in mam-
mary tissue may have been related to alterations in hor-
mone levels during the perimenopausal period. Indeed all
14 patients in whom these cells were found in Rosen's
case series, were aged between 40–50 years. It has also
been noted that MSGCs in the female genital tract are
associated with pregnancy and exogenous progestins.
Diagnostic pitfalls
Due to its rarity, few cases of MSGCs in benign breast
tumours have been described cytologically. Hence recog-
nition and correct interpretation of their presence is diffi-
cult, yet crucial to forming an accurate diagnosis. Incorrect
interpretation of these unusual cells as malignant cells can
lead to misdiagnosis of more sinister conditions, such as
malignant phyllodes tumor and metaplastic carcinoma.
Consequently treatment of a lesion bearing MSGCs could
potentially be misguided. Another diagnostic pitfall to be
aware of upon identifying multinucleated giant cells in
breast lesions is their resemblance histologically to osteo-
clast-like giant cells which are also infrequently reported
to occur in a similar spectrum of both benign and malig-
nant breast lesions [6-9]. A distinction must be made
between these two cell types as it has diagnostic and prog-
nostic implications. In fact osteoclast-like giant cells in
association with malignant breast epithelial cells is indic-
ative of a mammary carcinoma with postulated poor
prognosis. Several reports have noted a less favourable
outcome for patients with mammary carcinomas contain-
ing osteoclast-like giant cells when compared with con-
ventional ductal adenocarcinoma [9].
In a review article on this subject in 2004, Cai states that
it is the combination of osteoclast-like giant cells and can-
cer cells in association, which allows the diagnosis of this
Immunohistochemical stains on core breast biopsy tissue Figure 3
Immunohistochemical stains on core breast biopsy tissue. a. Case 1: Pancytokeratin. b. Case 1: SMA. c. Case 1: Vimen-
tin (arrow marks multinucleated giant cells in stroma). d. Case 2: Pancytokeratin. e. Case 2: SMA. f. Case 2: Vimentin (arrow 
marks multinucleated giant cells in stroma).
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rare type of adenocarcinoma, even from a fine needle
aspiration specimen [8]. However in scanty biopsy speci-
mens, the bland-appearing multinucleated cells may be
misinterpreted simply as foreign-body giant cells such as
that seen in necrosis of fat.
Therefore Cai cautions that it is the cytologic features of
the breast epithelial cells, rather than the presence of the
osteoclast-like giant cells in isolation, upon which the
diagnosis of mammary carcinoma with osteoclast-like
giant cells is based on. Thus, a careful search for malignant
epithelial cells should always be performed upon recogni-
tion of any osteoclast-like giant cells in a breast biopsy, to
avoid a false negative diagnosis [10]. Several cytological
differences are noted between MSGCs and osteoclast-like
giant cells to help in their differentiation. Multinucleated
stromal cells have multiple overlapping nuclei and scant
cytoplasm, and they are usually located within the stroma,
with no association with the epithelial cells [11]. In con-
trast, osteoclast-like giant cells have over 20 centrally
located nuclei, and are found primarily in the advancing
edges of the infiltrating tumour mass or in the lumen of
the cribriform epithelial ducts, and in fine needle aspira-
tion smears the osteoclast-like giant cells are intimately
admixed with malignant epithelial cells [12]. In phyllodes
tumors for example, which are uncommon fibroepithelial
neoplasms with a prominent stromal component and
where MSGCs may be seen on rare occasions, these partic-
ular multinucleated stromal cells are different from osteo-
clast-like giant cells, showing a linear nuclear arrangement
or floret-like pattern [3,6,13,14].
The immunohistochemical staining pattern is also differ-
ent for MSGCs and osteoclast-like giant cells. Tse
described the immunohistochemical profile of the infre-
quent MSGCs in phyllodes tumours, commenting that
both the MSGCs and stromal cells expressed vimentin
strongly but not desmin; and in some but not all fibroep-
ithelial tumours, both MSGCs and stromal cells expressed
actin weakly. These features suggest that MSGCs may be
off myofibroblastic differentiation [3].
Indeed both of our cases stained strongly positive for
vimentin though negative for actin, indicating likely
fibroblastic origin. On the other hand, osteoclast-like
giant cells have an immunohistochemistry profile typical
of histiocytic differentiation, staining positive for the typ-
ical osteoclast markers, CD68, CD1a, tartrate-resistant
acid phosphatase (TRAP), and negative for cytokeratin,
epithelial membrane antigen, lysozyme, and estrogen and
progesterone receptors. Their staining pattern thus rejects
any epithelial, endothelial or trophoblastic origin of these
cells [15].
Histological features and origin of MSGCs
The histogenesis of MSGCs remains obscure and contro-
versial however, with several conflicting reports in the lit-
erature [1,3,4]. As briefly mentioned above, the most
consistent finding with immunohistochemical studies is
that MSGCs stain strongly positive for Vimentin, which is
one of the Type II 1F proteins in the cytoskeleton and is
known to play a significant role in maintaining cell shape,
integrity of the cytoplasm, and stabilizing cytoskeletal
interactions [16]. Histopathological reports indicate that
cells showing Vimentin positivity is broadly suggestive of
a myofibroblastic origin [17]. Abd el-All, who reported on
the histopathological and immunohistochemical features
of breast spindle cell tumours, then suggests that the
Vimentin/CD34 positive fibroblast of mammary stroma
could be the result of differentiation from a pluripotential
mesenchymal precursor cell with the potential to differen-
tiate toward several mesenchymal lines [18]. MSGCs also
show inconsistent focal positive staining with histiocytic
markers such as alpha-1-antitrypsin, alpha-1-antichymot-
rypsin, HAM-56, CD34, and CD68. These markers of his-
tiocytic differentiation are more consistently found
positive in osteoclast-like giant cells. As shown in our two
cases MSGCs stain negatively with immunoperoxidase
stains for oestrogen and progesterone receptors, cytokerat-
ins (AE 1/3 and CAM 5.2), S100 protein, muscle specific
actin and desmin, further supporting their fibroblastic ori-
gin.
Differential Diagnosis
In our two cases had the presence of the bizarre multinu-
cleated giant cells within the stroma of the benign breast
fibroepithelial tumour been mistaken as evidence of
malignancy then this could have led to a misdiagnosis,
perhaps that of a malignant Phyllodes tumour (malignant
cystosarcoma phyllodes) as described briefly above, or
other breast carcinoma. MSGCs are similarly a rare find-
ing in Breast carcinomas [10,19]. In a recent review of lit-
erature published by Cai G regarding the presence
specifically of osteoclast-like multinucleated giant cells in
mammary carcinomas [10], the occurrence of MSGCs in a
variety of malignant tumours was also described. This
report noted their presence in a spectrum of invasive and
in-situ breast carcinomas and referred to their original
description in malignant breast lesions by Rosen [1].
Notably, Rosen also commented on the diagnostic impor-
tance and rarity of MSGCs found in mammary carcinomas
in his book 'Rosen's Breast Pathology' [11]. The bizarre
multinucleated giant cells in invasive breast carcinoma are
usually located within the stroma, with no relation to the
epithelial cells. In this setting these MSGCs are distin-
guishable from osteoclast-like giant cells also by their ple-
omorphism and their distinct immunoprofile, as alluded
to above and further described by Gupta [20].Diagnostic Pathology 2008, 3:33 http://www.diagnosticpathology.org/content/3/1/33
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The differential diagnosis upon recognition of MSGCs in
breast lesions also includes Breast spindle cell tumours
(BSCTs), and other hamartomas of the breast. BSCTs are a
heterogeneous group including benign and malignant
lesions, with different therapeutic and prognostic implica-
tions. Cytological examination followed by immunohis-
tochemistry staining is critical to differentiate BSCTs from
other breast lesions as well as to categorise the individual
subtypes of spindle cell tumour. An accurate diagnosis is
essential in order to appropriately manage the lesion and
predict the prognosis for the patient [18]. For example
with regard to myoepithelial tumours which are a subtype
of BSCT composed of a dominant to pure population of
myoepithelial cells, immunohistochemistry stains typi-
cally show positivity for actin, S-100, cytokeratin, p63 and
CD10, all of which are consistent with a myoepithelial
origin. These may be differentiated from fibroepithelial
tumours on the basis that the spindle cells stain negative
for CD34. Differentiation of myoepitheliomas into
benign and malignant lesions is based on further cyto-
logic features. Those features observed only in malignant
myoepithelial lesions include pleomorphism, coarse
nuclear chromatin, prominent nucleoli, high mitotic
activity and tumour necrosis [21].
Hamartomas are breast lesions with varying amounts of
benign epithelial elements, fibrous tissue, and fat and in
rare cases the occurrence of giant cells has been noted.
They lack a distinctive pathological appearance however
most authors agree on a general characteristic pattern of
interlobular fibrosis, which is defined as the presence of
lobules within a fibrotic stroma, which surrounds and
extends to between individual lobules and obliterates the
usual interlobular specialised loose stroma [22]. Unfortu-
nately however this pattern is not unique to hamartomas.
Other commonly described yet nonetheless inconsistent
features of hamartomas include the presence of varying
proportions of pseudo-angiomatous stroma, and adipose
tissue within the stroma [23]. Epithelial changes such as
hyperplasia without atypia, cystic change, apocrine meta-
plasia, and adenosis have been described in a smaller pro-
portion of hamartomas [23,24], as have other rare
features including microcalcification, myoid differentia-
tion, stromal oedema, and stromal giant cells. Further-
more, there are occasional case reports of coincidental in-
situ, or invasive ductal or lobular carcinoma occurring in
hamartomas [25]. Hence the correct identification of
hamartomas is important because there are the problems
of recurrence and coincidental epithelial malignancy.
However diagnosis is difficult, and not reliant solely on
any one histopathological technique or immunohisto-
chemistry stain, due to the presence of the various ele-
ments. A complete triple assessment of these lesions is
warranted to formulate the correct diagnosis, including
correlation of the clinical impression with the radiologi-
cally distinct imaging findings and the above pathological
features.
Conclusion
The presence of these pleomorphic, multinucleated large
cells in small specimens such as those obtained at fine
needle aspiration or core biopsy, may be misinterpreted as
a malignant process. The typical benign cytoarchitecture
of a fibroadenomas, in a background of naked multiple
nuclei indicates the benign nature of the lesion and has no
known malignant potential. Correct recognition and the
ability to differentiate these cells from malignant cells are
dependent on a combination of conventional diagnostic
pathological techniques: H&E and IHC staining using a
small panel of antibodies. Awareness of this phenomenon
is critical in facilitating accurate diagnosis and appropriate
management of the patient.
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